Edition:
India

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

2.29USD
19 Jan 2018
Change (% chg)

$0.17 (+8.02%)
Prev Close
$2.12
Open
$2.12
Day's High
$2.35
Day's Low
$2.05
Volume
147,282
Avg. Vol
88,302
52-wk High
$7.26
52-wk Low
$0.80

Chart for

About

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $55.61
Shares Outstanding(Mil.): 15.11
Dividend: --
Yield (%): --

Financials

BRIEF-Aradigm - FDA Advisory Committee Did Not Recommend Approval For Linhaliq

* ARADIGM REPORTS RESULTS OF FDA ADVISORY COMMITTEE MEETING ON LINHALIQ‍​

12 Jan 2018

BRIEF-Boxer Capital Reports 5.9 Pct Passive Stake In Aradigm Corp As Of Nov 30

* BOXER CAPITAL LLC REPORTS 5.9 PERCENT PASSIVE STAKE IN ARADIGM CORP AS OF NOVEMBER 30 - SEC FILING Source text: (http://bit.ly/2BDnINX) Further company coverage:

12 Dec 2017

BRIEF-Aradigm Announces FDA Advisory Committee Meeting For Linhaliq

* ARADIGM ANNOUNCES FDA ADVISORY COMMITTEE MEETING FOR LINHALIQ

01 Dec 2017

BRIEF-Aradigm Corp files for common stock offering of up to $20 mln

* Aradigm Corp files for common stock offering of up to $20 million - SEC filing‍​ Source text: (http://bit.ly/2lOJdUD) Further company coverage:

04 Nov 2017

BRIEF-Aradigm Q3 loss per share $0.26

* Aradigm corp - qtrly ‍rev $2.7 million versus $50,000​ Source text for Eikon: Further company coverage:

02 Nov 2017

Earnings vs. Estimates